The Pharmacology of Acute Lung Injury in Sepsis
2011

The Pharmacology of Acute Lung Injury in Sepsis

publication Evidence: moderate

Author Information

Author(s): Brian Michael Varisco

Primary Institution: Cincinnati Children's Hospital Medical Center

Hypothesis

What are the pharmacologic and nonpharmacologic strategies to treat acute lung injury (ALI) secondary to sepsis?

Conclusion

Despite multiple trials, the only therapy that has demonstrated clear benefit with regards to mortality is the employment of low tidal volume ventilation strategy.

Supporting Evidence

  • Acute lung injury is a major cause of death in sepsis.
  • Low tidal volume ventilation has shown a clear benefit in mortality.
  • Restrictive fluid management strategies are well supported despite no mortality benefit.

Takeaway

Acute lung injury from sepsis is serious and hard to treat, but using lower tidal volumes when ventilating patients can help save lives.

Methodology

This review discusses the epidemiology, pathophysiology, and treatment strategies for ALI in sepsis.

Limitations

The review highlights that many therapies have failed in larger human trials and that there is a lack of ability to phenotype ALI meaningfully.

Participant Demographics

The review mentions both adult and pediatric populations.

Digital Object Identifier (DOI)

10.1155/2011/254619

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication